Candel Therapeutics, Inc. entered a $100 million purchase agreement with RTW Investments, effective February 19, 2026, contingent on FDA approval of their product CAN-2409 for prostate cancer, with royalties tied to future sales; they reported $119.7 million in preliminary cash as of December 31, 2025.